Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.
Rufinamide was approved by the US Food and Drug Administration on November 14, 2008 as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults. Its official FDA-approved labeling does not mention use in the treatment of partial seizures inasmuch as clinical trials submitted to the FDA were marginal. However, several recent clinical trials suggest that the drug has efficacy for partial seizures It is marketed under the brand name Banzel. It is also marketed in the European Union under the brand name Inovelon.
The mechanism of action of rufinamide is unknown. There is some evidence that rufinamide can modulate the gating of voltage-gated sodium channels, a common target for antiepileptic drugs. A recent study indicates subtle effects on the voltage-dependence of gating and the time course of inactivation in some sodium channel isoforms that could reduce neuronal excitability. However, this action cannot explain the unique spectrum of activity of rufinamide.

Chemical Name	Rufinamide
Synonyms	1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide;1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide;
CAS No.	106308-44-5
Molecular Formula	C10H8F2N4O
Molecular Weight	238.19400
PSA	73.80000
LogP	1.40380

UNII	WFW942PR79

Appearance & Physical State	white powder
Density	1.52 g/cm3
Boiling Point	473.8ºC at 760 mmHg
Flash Point	240.4ºC
Refractive Index	1.634
Storage Condition	-20ºC
Vapor Pressure	3.81E-09mmHg at 25°C